← Leaderboards
Hua Shi
State University Of New York At Albany
$1,052,483
Attributed
$2,311,083
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $645.7K · FY2009–20$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,311,083 · 3
By mechanism
R01$1,886,208 · 2
R21$424,875 · 1
Top collaborators
- John T Lis4 shared
- Albert Millis2 shared
- Charles M Perou2 shared
- Ing-Nang Wang2 shared
Most similar at State University Of New York At Albany
Same institution · by research overlap
- Ing-Nang Wang$2,487,259
- Albert Millis$206,116
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsBaseCellsAptamerSurfaceBiological ModelsSpecificityPharmaceutical PreparationsLeadMacromoleculeGene ExpressionSchemeDrug DiscoveryMembrane ProteinsBinding (Molecular Function)AffinityTumorPathway InteractionsMalignant NeoplasmsGrowthPhenotypeDna RepairDefectDna Sequence
Grant awards (8)
Aptamer-Enabled Modification of Bacteriophage Host Range$193,125
R21 · FY2020 · AI
Aptamer-Enabled Modification of Bacteriophage Host Range$231,750
R21 · FY2019 · AI
Use of aptamers in dissecting the HSF-regulated cancer-enabling network$308,587
R01 · FY2012 · CA
Use of aptamers in dissecting the HSF-regulated cancer-enabling network$308,706
R01 · FY2011 · CA
Use of aptamers in dissecting the HSF-regulated cancer-enabling network$318,371
R01 · FY2010 · CA
Target Validation and Drug Development with Aptamers for Basal-like Breast Cancer$304,874
R01 · FY2010 · CA · contact PI
Use of aptamers in dissecting the HSF-regulated cancer-enabling network$332,195
R01 · FY2009 · CA
Target Validation and Drug Development with Aptamers for Basal-like Breast Cancer$313,475
R01 · FY2009 · CA · contact PI